[Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure].
Study purpose - to assess clinical and hemodynamic parameters in patients with ischemic heart disease (IHD) with and without use of metabolic therapy with trimetazidine MB. Seventy four patients with IHD, 40 of whom in addition to the main therapy for 3 months received metabolic preparation trimetazidine MB. Number of anginal attacks and inhalations of nitroglycerin significantly decreased and parameters of hemodynamics improved after 3 months in patients who received trimetazidine MB. Long-term use of trimetazidine MB in patients with IHD is advisable.